Gene therapy and genome editing for primary immunodeficiency diseases
In past two decades the gene therapy using genetic modified autologous hematopoietic stem cells (HSCs) transduced with the viral vector has become a promising alternative option for treating primary immunodeficiency diseases (PIDs). Despite of some pitfalls at early stage clinical trials, the field...
Main Authors: | Zhi-Yong Zhang, Adrian J. Thrasher, Fang Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2020-03-01
|
Series: | Genes and Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352304219300510 |
Similar Items
-
Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease
by: Elena Blanco, et al.
Published: (2020-11-01) -
Novel genome-editing tools to model and correct primary immunodeficiencies
by: Lisa M Ott De Bruin, et al.
Published: (2015-05-01) -
Gene Therapy for Primary Immunodeficiency
by: Benjamin C. Houghton, et al.
Published: (2021-01-01) -
Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing
by: C. Eguizabal, et al.
Published: (2020-10-01) -
Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency
by: Claudia A Montiel-Equihua, et al.
Published: (2009-12-01)